◀ Back to EGF
EGF — PLA2G4A
Text-mined interactions from Literome
Yang et al., J Membr Biol 2001
:
Taken together,
EGF stimulates Erk1/2 ; p38 and
cPLA2 activity
Huang et al., J Biol Chem 2002
(MAP Kinase Signaling System) :
It has been reported that
epidermal growth factor (EGF) induces
cPLA(2) activation or cPLA(2) expression and subsequent AA release ... Immunoprecipitation experiments showed that
EGF induced increased p11 binding to
cPLA(2) in a time- and dose dependent manner
Xu et al., J Neurochem 2002
(MAP Kinase Signaling System) :
Epidermal growth factor (EGF) also
stimulated phosphorylation of ERK1/2 and
cPLA2 [ largely through a protein kinase C ( PKC ) -independent pathway ], but EGF did not evoke AA release
Kisslov et al., Biochim Biophys Acta 2012
(Colonic Neoplasms) :
EGF caused a rapid activation of
cPLA(2)a which coincided with a significant increase in cell proliferation
Adachi et al., Hepatology 1995
:
These results suggest that HGF as well as
EGF causes AA release, probably through activation of
cPLA2 mediated by MAP kinases, and that PGs, metabolites of AA, might play a pivotal role in hepatocyte proliferation in an autocrine mechanism
Schalkwijk et al., Eur J Biochem 1995
:
In the present study we demonstrate a rapid transient
EGF induced activation of this
cPLA2 and an EGF induced increase in phosphorylation of the cPLA2 ... The
EGF induced activation of
cPLA2 is reversed upon phosphatase treatment showing phosphorylation dependent activation of the cPLA2
Maxwell et al., Biochem J 1993
:
Cultured rat mesangial cells were used as a model system to test the
effects of
EGF and PMA on the regulation of
cPLA2 gene expression ...
EGF and PMA both produced sustained
increases in
cPLA2 mRNA levels, with a parallel increase in enzyme activity over time ... Actinomycin D treatment entirely abrogated the
effect of
EGF on
cPLA2 mRNA accumulation
Croxtall et al., Biochem Pharmacol 1996
(Adenocarcinoma) :
This concept is supported by the fact that a peptide Lc13-25 ( 10-200 micrograms/mL ), derived from the N-terminus of lipocortin 1, also inhibits
activation of
cPLA2 by
EGF in these cells
Sato et al., Prostaglandins 1997
(Carcinoma, Squamous Cell) :
These results suggest that
EGF augments the production of PGE2 by
increasing not only the activity of
cPLA2 but also the production of COX-2 in A431 cells
Cybulsky et al., Kidney Int 1998
(Glomerulonephritis, Membranous) :
Unlike complement,
activation of
cPLA2-wt by
epidermal growth factor was dependent on PKC, and was augmented significantly by p42 MAPK
Muthalif et al., Proc Natl Acad Sci U S A 1998
:
NE-, Ang II-, and
EGF stimulated MAPK and
cPLA2 were reduced by inhibitors of cytochrome P450 ( CYP450 ) and lipoxygenase but not by cyclooxygenase